La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Little Green Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul Long

Amministratore delegato

AU$734.1k

Compenso totale

Percentuale dello stipendio del CEO	25.3%
Mandato del CEO	less than a year
Proprietà del CEO	0.8%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Jun 30

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Sep 06

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Feb 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Long rispetto agli utili di Little Green Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	AU$734k	AU$186k	-AU$8m

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 491.13K ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 299.11K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Paul con le performance aziendali.

AMMINISTRATORE DELEGATO

Paul Long

less than a year

Mandato

AU$734,086

Compensazione

Mr. Paul Long serves as Executive Chair at Reset Mind Sciences Limited since February 2024. He serves as a Director of WellteQ Pte. Ltd.As a WellteQ co-founder, Mr. Long is an active contributor to the vi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Long	Chief Executive Officer	less than a year	AU$734.09k	0.80% A$ 237.8k
Angus Caithness	CFO & Executive Director	1.6yrs	AU$986.03k	3.8% A$ 1.1m
Fleta Solomon	Executive Director	less than a year	AU$856.56k	7.25% A$ 2.1m
Alistair Warren	General Counsel & Company Secretary	4.1yrs	Nessun dato	Nessun dato
Celia Young	Head of Marketing	no data	Nessun dato	Nessun dato
Gabriela Franz	Head of Commercial Operations Europe	1.3yrs	Nessun dato	Nessun dato
Melanie Pugliese	Head of Engagment	2.8yrs	Nessun dato	Nessun dato
Brian Westergaard	Head of IT	2.8yrs	Nessun dato	Nessun dato
Barb Fullerton	Head of Sales & Distribution AU	no data	Nessun dato	Nessun dato

1.6yrs

Durata media

Gestione esperta: Il team dirigenziale di LGP non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Angus Caithness	CFO & Executive Director	6.5yrs	AU$986.03k	3.8% A$ 1.1m
Fleta Solomon	Executive Director	7.3yrs	AU$856.56k	7.25% A$ 2.1m
Neale Fong	Independent Non Executive Director	5.8yrs	AU$84.92k	0.51% A$ 152.0k
Michael Lynch-Bell	Independent Non Executive Chairman	5.8yrs	AU$169.52k	0.58% A$ 172.3k
Joe Kosterich	Medical Advisor	no data	Nessun dato	Nessun dato
Beatriz Vicen Banzo	Independent Non-Executive Director	2.1yrs	AU$90.15k	0.017% A$ 4.9k

5.8yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LGP sono considerati esperti (durata media dell'incarico 5.8 anni).

Little Green Pharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Little Green Pharma Ltd, Annual General Meeting, Feb 21, 2024

Little Green Pharma Announces CEO Changes, Effective 29 August 2023

Little Green Pharma Ltd, Annual General Meeting, Jan 31, 2023

Less than half of directors are independent

Recent updates

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Now 23% undervalued after recent price drop

Estimating The Fair Value Of Little Green Pharma Ltd (ASX:LGP)

Full year 2024 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2026

Now 24% undervalued after recent price drop

Now 22% undervalued after recent price drop

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

New major risk - Financial position

Little Green Pharma Ltd, Annual General Meeting, Feb 21, 2024

First half 2024 earnings released: AU$0.007 loss per share (vs AU$0.004 loss in 1H 2023)

Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet

Little Green Pharma Limited Announces Australian Clinical Study Finds Medicinal Cannabis Significantly Improves Pain, Quality of Life, Moderate-Severe Anxiety and Depression

Little Green Pharma Announces CEO Changes, Effective 29 August 2023

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

Now 20% undervalued after recent price drop

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)

Little Green Pharma Ltd, Annual General Meeting, Jan 31, 2023

Little Green Pharma Ltd. Obtains Ethics Approval for its Proposed Multi-Site, Placebo-Controlled Pharmacokinetic and Phase III Efficacy and Safety Trial

Little Green Pharma Ltd Significantly Expands Flower Portfolio

Little Green Pharma Ltd Provides Update on French Trial Extension

Less than half of directors are independent

Little Green Pharma Ltd Appoints Beatriz Vicén Banzo as Non-Executive Director

Little Green Pharma Ltd, Annual General Meeting, Aug 12, 2022

Price target decreased to AU$1.04

Insufficient new directors

Executive Director exercised options to buy AU$1.7m worth of stock.

Insufficient new directors

Insufficient new directors

Little Green Pharma Ltd Secures First Registration for Locally Produced Cannabis Medicine in Denmark

Price target decreased to AU$1.04

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Little Green Pharma Ltd (ASX:LGP) acquired GACP cultivation and GMP licensed medicinal cannabis asset in Denmark for CAD 20 million.

Little Green Pharma Ltd Receives Firm Purchase Order from Deutsche Medizinalcannabis Gmbh

Little Green Pharma Ltd Delivers First French Shipment

First half 2021 earnings released: EPS AU$0.004 (vs AU$0.077 loss in 1H 2020)

Little Green Pharma Ltd Announces Supply of Medicinal Cannabis Oil Products to Enrolled Patients as Well as Providing Funding for Study Costs for the QUality uality of Life Evaluation STudy

Little Green Pharma Ltd announced that it expects to receive AUD 22.1 million in funding

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Little Green Pharma Ltd Exports First Commercial Shipment

Little Green Pharma Ltd Announces it has Selected Primary Supplier of Medicinal Cannabis Oils for French National Trial of Medicinal Cannabis in Partnership Intsel Chimos

New 90-day high: AU$0.65

Little Green Pharma Ltd Announces TGA's final Decision to Both Down-Schedule Certain Medicinal Cannabidiol Products from Schedule 4 to Schedule 3

New 90-day high: AU$0.61

Little Green Pharma Ltd Provides Update on Its Export of the Largest Australian Commercial Shipment

New 90-day high: AU$0.36

Little Green Pharma Ltd Announces Post-Market Survey Test Results

New 90-day low - AU$0.31

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media